Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Antares Pharma, Inc. (the "Company") was held on June 11, 2020. The following proposals, all of which were set forth in the Company's definitive proxy statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 27, 2020, were voted on at the Annual Meeting. Set forth below are the final voting results for each of the proposals submitted to a vote of the shareholders.

1. The nominees for election as Class I directors of the Company's Board of Directors, each for a three year term, were elected based upon the following vote:





          Nominee              For      Withheld  Broker Non-Votes

Leonard S. Jacob, MD, Ph.D. 56,036,903 18,059,855 57,320,411 Peter S. Greenleaf 48,163,527 25,933,231 57,320,411

2. The proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers ("say-on-pay"), was approved based upon the following votes:





   For      Against   Abstain Broker Non-Votes
61,378,512 11,757,849 960,397    57,320,411

3. The proposal to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020 was approved based upon the following votes:





    For      Against   Abstain  Broker Non-Votes
125,658,406 4,670,436 1,088,327      None.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses